Edgewise Therapeutics (EWTX) Cash & Equivalents (2020 - 2026)

Edgewise Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $33.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 33.47% year-over-year to $33.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.2 million (down 33.47% YoY) and the FY2025 annual result came in at $61.1 million, up 46.76% from the prior year.
• Cash & Equivalents fell to $33.2 million in Q1 2026 per EWTX's latest filing, from $61.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $563.3 million in Q3 2025 and troughed at $22.0 million in Q4 2022.
• A 5-year average of $145.6 million and a median of $48.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 1394.37% in 2024, then slumped 90.63% in 2025.
• Over 5 years, Cash & Equivalents stood at $22.0 million in 2022, then jumped by 291.47% to $86.1 million in 2023, then slumped by 51.61% to $41.7 million in 2024, then surged by 46.76% to $61.1 million in 2025, then sank by 45.69% to $33.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $33.2 million, $61.1 million, and $563.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.